Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. engages in the provision of medical services. The firm offers specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropodist, neurological functions, kinesiology, and dental services. Its multi-disciplinary healthcare services and protocols are directed at assessment, treatment, management, rehabilitation, and prevention through its clinics, affiliate clinics, retirement homes, and long-term facilities. The firm operates through the following business segments: healthcare services, and product manufacturing and development. The company was founded by Michael H. Rouse on November 27, 2000 and is headquartered in Bellevue, WA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Integrated Sciences, Inc. engages in the provision of medical services. The firm offers specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropodist, neurological functions, kinesiology, and dental services. Its multi-disciplinary healthcare services and protocols are directed at assessment, treatment, management, rehabilitation, and prevention through its clinics, affiliate clinics, retirement homes, and long-term facilities. The firm operates through the Healthcare Services and Product Sales segments. The company was founded by Michael H. Rouse on November 27, 2000 and is headquartered in Bellevue, WA.

Novo Integrated Sciences' Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Smart Healthcare Solution Provider, TiaTech USA Inc.

Novo Integrated Sciences' Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Tranquility Lifestyle Solutions

The stock price of Novo Integrated Sciences (NVOS) fell by 61.94% in the most recent trading session. This is why.

Novo Integrated Sciences (NVOS) Stock: Why It Dropped 61.94%

Novo Integrated Sciences, Inc. Announces Pricing of $2.0 Million Public Offering

Novo Integrated Sciences' Subsidiary, Clinical Consultants International, Signs Consulting Services Agreement with Information Technology Company, Softhread

VAUGHAN, Ontario--(BUSINESS WIRE)---- $NVOS #HealthCanadaNPN--Embracing Technology and Innovation “Key” to Easing Healthcare Crisis. Greater Toronto Area Company Improving Healthcare Delivery and Treatments.

Embracing Technology and Innovation “Key” to Easing Healthcare Crisis

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal third quarter ended May 31, 2022. Robert Mattacchione, Novo's CEO and Board Chairman, stated, “Novo achieved record revenue in the fiscal 202

Novo Integrated Sciences Reports Record Revenue of $13.8 million in Fiscal 2022 Third Quarter

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today announced that its preliminary unaudited revenue for the third quarter of fiscal 2022 is expected to be in the range of $13.4 million to $13.9 million, an increase of approximately 367% t

Novo Integrated Sciences Announces Preliminary Revenue Range for Fiscal 2022 Third Quarter

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences' Chairman and CEO to Present at the AAPI CEO Forum on the Future of Healthcare: Technology, Transformation and Beyond

Novo Integrated Sciences' Chairman and CEO to Present at the AAPI CEO Forum on the Future of Healthcare: Technology, Transformation and Beyond

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences' Chief Medical Officer, Dr. Joseph M. Chalil, Selected as Top Physician of the Year by IAOTP

Novo Integrated Sciences' Chief Medical Officer, Dr. Joseph M. Chalil, Selected as Top Physician of the Year by IAOTP

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences Reports Fiscal 2022 Second Quarter Financial Results.

Novo Integrated Sciences Reports Fiscal 2022 Second Quarter Financial Results

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences Completes Acquisition of Clinical Consultants International LLC and Appoints Dr. Joseph Chalil as Chief Medical Officer

Novo Integrated Sciences Completes Acquisition of Clinical Consultants International LLC

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences Signs MOU with Boditech Med, a Global Point-of-Care Testing Leader, to Market and Distribute in North America

Novo Integrated Sciences Signs Memorandum of Understanding with Boditech Med, a Global Point-of-Care Testing Leader, to Market and Distribute in North America

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences' PRO-DIP® Issued U.S. Patent for Oral Pouch Delivery System Technology

Novo Integrated Sciences' PRO-DIP® Issued U.S. Patent for Oral Pouch Delivery System Technology

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, has signed a Membership Interest Purchase Agreement (“MIPA”) to acquire Clinical Consultants International LLC (“CCI”) in an all-stock transaction (the “Transaction”). The transaction is expected to close no later than April 15, 2022. Esta

Novo Integrated Sciences Enters into Purchase Agreement to Acquire Clinical Consultants International LLC

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences to Participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest

Novo Integrated Sciences to Participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences' IoNovo Iodide Granted Natural Product Number (NPN) by Health Canada

Novo Integrated Sciences' IoNovo Iodide Granted Natural Product Number (NPN) by Health Canada

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences' IoNovo for Kids Pure Iodine Oral Spray Granted Natural Product Number by Health Canada Proven to be Safe and Effective.

Novo Integrated Sciences' IoNovo for Kids Pure Iodine Oral Spray Granted Natural Product Number (NPN) by Health Canada

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences Reports First Quarter Financial Results

Novo Integrated Sciences Reports First Quarter Financial Results

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences Announces Signing of a Master Facility License Agreement with LA Fitness in Canada

Novo Integrated Sciences Announces the Signing of a Master Facility License Agreement with LA Fitness in Canada

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences Granted Natural Product Number (NPN) by Health Canada for IoNovo Iodine Branded Product

Novo Integrated Sciences Granted Natural Product Number (NPN) by Health Canada for IoNovo Iodine Branded Product

BELLEVUE, Wash.--(BUSINESS WIRE)--Novo Integrated Sciences Reports Fiscal Full Year 2021 Financial Results

Novo Integrated Sciences Reports Fiscal Full Year 2021 Financial Results

Novo Integrated Sciences Inc (NASDAQ: NVOS) has acquired 91% of Terragenx through an all-share transaction at $3.35 per share.  The human immune system uses iodine to deactivate viruses in the bloodstream, facilitating the production of antibodies for various indications.

Novo Integrated Sciences Acquires Majority Stake in Terragenx

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences Acquires 91% Stake in Terragenx and IP for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient

Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #Benzinga--Novo Integrated Sciences' subsidiary, Novo Healthnet Limited, and EK-Tech Solutions Announce Joint Venture for Enhanced Telehealth Platform

News for Novo Integrated Sciences, Inc. Stock (NVOS)